
Sign up to save your podcasts
Or
Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Tune in as we chat with Dr. Yasmin Karimi from the University of Michigan about the latest breakthroughs in treatment, including combination therapies, CAR T-cell therapy and bispecific antibodies. Discover how these innovations are offering new hope and pathways to cures for patients.
Mentioned on this episode:
Additional LLS Support Resources:
Support for this episode provided by Genmab US, Inc.
The post Emerging Therapies and Hope: Diffuse Large B-cell Lymphoma first appeared on The Bloodline with LLS.
4.9
4343 ratings
Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Tune in as we chat with Dr. Yasmin Karimi from the University of Michigan about the latest breakthroughs in treatment, including combination therapies, CAR T-cell therapy and bispecific antibodies. Discover how these innovations are offering new hope and pathways to cures for patients.
Mentioned on this episode:
Additional LLS Support Resources:
Support for this episode provided by Genmab US, Inc.
The post Emerging Therapies and Hope: Diffuse Large B-cell Lymphoma first appeared on The Bloodline with LLS.
8,555 Listeners
15,637 Listeners
1,310 Listeners
12,557 Listeners
4,748 Listeners
111,673 Listeners
1,071 Listeners
7,033 Listeners
13 Listeners
5,458 Listeners
14,537 Listeners
8,204 Listeners
792 Listeners
40,960 Listeners
523 Listeners